Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.

Clinical and translational medicine - 1 May 2024

Tang Qin, Hu Guanghui, Sang Ye, Chen Yulu, Wei Guangyan, Zhu Meiyan, Chen Mengke, Li Shiyong, Liu Rengyun, Peng Zhenwei

Abstract excerpt

BACKGROUND: Hotspot mutations in the promoter of telomerase reverse transcriptase (TERT) gene are the most common genetic variants in hepatocellular carcinoma (HCC) and associated with poor prognosis of the disease. However, no drug was currently approved for treating TERT promoter mutation positive HCC patients. Here, we aim to explore the potential therapeutic strategy for targeting TERT promoter mutation in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Proteins

Share to Liver Neoplasms

Share to Polo-Like Kinase 1

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 38769666
DOI: 10.1002/ctm2.1703
PMCID: PMC11106514

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.PMID 38769666Read ↗

Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular CarcinomaSemantic proximity Read ↗

Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.Semantic proximity Read ↗

TERT promoter mutations in primary liver tumors.Semantic proximity Read ↗

Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.Semantic proximity Read ↗

TERT promoter mutations in thyroid cancer.Semantic proximity Read ↗

Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutationsSemantic proximity Read ↗

Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.Semantic proximity Read ↗

Understanding TERT Promoter Mutations: A Common Path to Immortality.Semantic proximity Read ↗

Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinomaSemantic proximity Read ↗

Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.Semantic proximity Read ↗

Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma.Semantic proximity Read ↗

Association of TERT promoter mutations with early recurrence in hepatocellular carcinoma: a subgroup analysis in a Vietnamese cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.